GST-π、TopoⅡ、P-gp、Ki-67及P53联合测定在结直肠癌中的表达及应用研究

Expression and Application of GST-π,TopoⅡ,P-gp,Ki-67 and P53 Joint Determination in Colorectal Cancer

目的:探讨结直肠癌组织中正谷胱甘肽-S-转移酶-π(GST-π)、DNA拓扑异构酶(TopoⅡ)、P-糖蛋白(P-gp)、Ki-67抗原(Ki-67)及P53基因(P53)的表达及临床意义。方法:选取2014年1月-2015年6月本院收治的术前未做化疗的24例结直肠癌患者作为研究对象,根据预后情况将其分为预后生存<1年组8例和预后生存>1年组16例,分析GST-π、TopoⅡ、P-gp、Ki-67及P53表达与临床病理特征的关系,比较两组患者GST-π、TopoⅡ、P-gp、Ki-67及P53的表达阳性率。结果:24例结直肠癌患者,GST-π表达阳性9例(低度表达7例,中度表达2例),TopoⅡ表达阳性23例(低度表达15例,中度表达8例),P-gp表达阳性23例(低度表达8例,中度表达15例),Ki-67表达阳性24例(低度表达3例,中度表达11例,高度表达10例),P53表达阳性10例(低度表达3例,中度表达3例,高度表达4例)。预后生存>1年组GST-π、P53的表达阳性率均为12.5%,显著低于预后生存<1年组,比较差异均有统计学意义(P<0.05),而在TopoⅡ、P-gp、Ki-67方面比较差异无统计学意义(P>0.05)。结论:联合检测GST-π、TopoⅡ、P-gp、Ki-67及P53的表达有助于结直肠癌早期发现及评估患者预后,值得临床推广。

Objective： To investigate the expression and its clinical significance of GST- π, TopoⅡ, P-gp, Ki-67and P53 in colorectal cancer tissue.Method： A total of 24 cases of colorectal cancer who had not been treated before surgery in our hospital from January 2014 to June 2015 were selected as the research objects, they were divided into the prognosis survival less than 1 year group with 8 cases and the prognosis survival more than 1 year group with 16 cases according to the prognosis, the relationship between GST-π, TopoⅡ, P-gp, P53, Ki- 67 expression and clinical pathological features were analyzed and the positive expression rate of GST- π , TopoⅡ, P-gp, P53, Ki-67 were compared.Result： For 24 cases of colorectal cancer, GST-π expression was positive in 9 eases （ low expression in 7 cases, moderate expression in 2 cases ）, TopoⅡ expression was positive in 23 cases （ low expression in 15 cases, moderate in 8 cases ）, P-gp expression was positive in 23 cases （ low expression in 8 cases, moderate in 15 cases ）, Ki-67 expression was positive in 24 cases （ low expression in 3 eases, moderate in 11 cases, highly expressed in 10 cases ）, P53 expression was positive in 10 eases （ low expression in 3 cases, moderate in 3 eases, highly expressed in 4 cases ） .The prognosis survival more than 1 year group of GST-π and P53 expression positive rate was all 12.5%, significantly lower than that of the prognosis survival less than 1 years group, the differences were statistically significant （ P〈o.05 ）, and there were no significant differences in TopoⅡ, P-gp and Ki-67 （P〉0.05） .Conclusion： Combined detection of GST-π , P-gp, TopoⅡ, Ki-67 and P53 contribute to colorectal cancer early diagnosis and evaluate the prognosis of patients, it is worthy of clinical promotion.